Dopaminergic Modulation of Cognition and Psychomotor Function
A recent study at our lab showed increased episodic memory consolidation and response readiness after treatment with methylphenidate in healthy volunteers. The investigators seek to replicate and extend these findings. Furthermore the pharmacological specificity of these effects will be studied. Since methylphenidate has an effect on two neurotransmitters, dopamine and noradrenaline, either could be responsible for the observed effects. In order to explore the dopaminergic contribution to this effect, the study proposed here includes not only methylphenidate but also levodopa/carbidopa, which only affects dopamine and not noradrenaline.
In this study, 20 healthy males and females between 18 and 45 years of age will participate. They will be recruited via advertisements at Maastricht University and in local newspapers.
Participants will be treated once with methylphenidate, once with levodopa/carbidopa and once with placebo. All medications will be administered orally with a capsule.
It is hypothesized that methylphenidate and levodopa/carbidopa will both enhance episodic memory consolidation and improve response readiness
Episodic Memory Consolidation
Drug: Methylphenidate 40 mg
Drug: Levodopa/carbidopa 125 mg
Drug: Domperidon 10 mg
|Study Design:||Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
|Official Title:||Dopaminergic Modulation of Cognition and Psychomotor Function|
- Behavioral score on the Word learning test [ Time Frame: 1 day ] [ Designated as safety issue: No ]Number of words recalled in the word learning test
- CNV amplitude [ Time Frame: 1 day ] [ Designated as safety issue: No ]Amplitude of the CNV wave in the EEG
- Reaction time on the CNV [ Time Frame: 1 day ] [ Designated as safety issue: No ]Reaction time in the response preparation task in which CNV is measured
|Study Start Date:||November 2010|
|Study Completion Date:||June 2012|
|Primary Completion Date:||June 2012 (Final data collection date for primary outcome measure)|
In this study, a crossover design is applied. All participants receive all three treatments in randomized order on separate days.
Drug: Methylphenidate 40 mg
Oral dose 40 mg
Other Name: Ritalin RVG 03957Drug: Levodopa/carbidopa 125 mg
oral dose, 100 mg levodopa, 25 mg carbidopa in one capsule
Other Name: Sinemet RVG08740Drug: Domperidon 10 mg
Domperidon 10 mg
Other Name: Domperidon RVG 23565
Please refer to this study by its ClinicalTrials.gov identifier: NCT01218425
|Maastricht, Limburg, Netherlands, 6200|
|Principal Investigator:||Eric Vuurman, Dr.||Dept Neuropsychology and Psychopharmacology, Maastricht University|